Samson Clinical just hit a major milestone. The first participant has been successfully dosed in its Phase 3 clinical trial for sublingual minoxidil—a formulation designed specifically to treat male pattern baldness.
Why This Matters
- Androgenetic alopecia (AGA) affects up to 80% of men over their lifetime.
- Current treatments often suffer from compliance issues and inconsistent results.
- Sublingual delivery offers a non-invasive, fast-acting, and potentially safer alternative.
Inside the SAM-002 Study
- Type: Randomised, controlled Phase 3 trial
- Location: Multicentre sites across Australia
- Intervention: Sublingual minoxidil vs placebo
- Target: Men with AGA
- Completion: Recruitment expected to finish by Q3 2025
- ClinicalTrials.gov ID: NCT06924632
The Vision Behind It
Prof. Rodney Sinclair, founder of Samson Clinical, pioneered the use of low-dose oral minoxidil in 2018 for female pattern baldness. Now, he’s pushing the boundaries further:
“Dosing our first participant is a significant step forward in bringing sublingual minoxidil to a broader patient population.”
The goal: develop a formulation that’s more effective, more convenient, and better tolerated than current topical or oral therapies.
Key Benefits of Sublingual Minoxidil
- Avoids first-pass metabolism (potential for fewer side effects)
- Faster absorption into the bloodstream
- More user-friendly than daily topical applications
What’s Next?
With the first participant enrolled and more sites ramping up recruitment, Samson Clinical is on track to complete enrolment by late 2025. If successful, this study could redefine the standard of care for male hair loss.
